This is a working overview of lyophilized powder, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from C-terminal region of human growth hormone |
| Approximate molecular mass | About 1.8 kDa | Varies with sequence length and counterions |
| Confirmed receptor target | None established | No confirmed growth hormone receptor agonism |
| Reported in vitro activity | Lipolysis stimulation and lipogenesis inhibition | Observed mainly in adipocyte models; human relevance uncertain |
| Regulatory status | Not approved as a drug in major markets | May be treated differently across jurisdictions; not a recognized dietary ingredient in some countries |
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Memphis was the smallest of Northwest Airlines' three domestic hubs. The carrier utilized all the gates in Concourse B, as well as some in A and C. As of 2004, it operated about 210 daily flights to more than 80 destinations. The airport had mainline flights to cities such as Boston and San Francisco. Northwest Airlink flew to communities within Tennessee and across the South, like Baton Rouge and Chattanooga. The hub had international service to three countries in North America and one in Europe. Northwest offered a daily flight to Amsterdam; it had replaced KLM on the route in 2003. Other destinations included Montego Bay and Toronto. The hub's shortest flight was the one to Tupelo, Mississippi, on Saab 340 turboprops, while the longest was the DC-10 service to Amsterdam. Northwest was acquired by Delta Air Lines in 2008. Delta maintained Memphis as a hub, offering 240 flights per day in 2009. However, due to high fuel costs, the company made Memphis subordinate to its hub in Atlanta. The airport's role changed to handling traffic that exceeded Atlanta's capacity, and flights were gradually scaled back. Delta discontinued the Amsterdam link in September 2012; as the hub shrank, so did the amount of connecting traffic that supported the flight. The following year, Pinnacle Airlines Corp. moved its headquarters out of the city. The holding company owned Pinnacle Airlines, formerly known as Express Airlines I. Delta closed the hub in September 2013, decreasing the number of daily departures from 94 to 60.
==== Historic safety concerns ==== In 1952, Kuroya and his colleagues attempted to identify an infectious agent in human tissue samples at Tohoku University Hospital, Sendai, Japan. The samples were taken from the lung of a newborn child that was affected by fatal pneumonia. The primary isolate from the samples was passaged in mice and subsequently in embryonated eggs. The isolated infectious agent was later called Sendai virus, which was used interchangeably with the name "hemagglutinating virus of Japan". Kuroya and his colleagues were convinced that they isolated the virus, which is a new etiological agent for human respiratory infections. Later in 1954, Fukumi and his colleagues at the Japan National Institute of Health put forward an alternative explanation for the origin of the virus. It was suggested that the mice used to passage the virus were infected with the mouse virus. Thus, mouse virus was later transferred to embryonated eggs, isolated and finally named the Sendai virus. This explanation of Fukumi, pointing to the mouse rather than the human origin of the virus, has been supported by numerous scientific data later. The historical aspects of the Sendai virus isolation and controversy behind it are well described in the review. Thus, for some time, it was erroneously assumed that Sendai virus is human disease causing pathogen. The incorrect assumption that the virus was isolated from human infectious material is still reported by Encyclopædia Britannica and by ATCC in the description of the history of the viral isolate Sendai/52.
Pre-Columbian Mesoamericans' use of obsidian was extensive and sophisticated; including carved and worked obsidian for tools and decorative objects. Mesoamericans made use of a variety of weapons using obsidian, such as macuahuitl, a type of sword with obsidian blades lining a wooden shaft, or the tepoztopilli, a polearm with a leaf or spade shaped wooden head lined with blades in a similar manner. Spanish sources describe these weapons as being able to kill and inflict terrible injuries. Obsidian mirrors were used by some Aztec priests to conjure visions and make prophecies. They were connected with Tezcatlipoca, god of obsidian and sorcery, whose name can be translated from the Nahuatl language as 'Smoking Mirror'. In Chile obsidian tools from Chaitén Volcano have been found as far away as in Chan-Chan 400 km (250 mi) north of the volcano, and also in sites 400 km south of it.
== Types == In mammals, NADPH oxidase is found in two types: one in white blood cells (neutrophilic) and the other in vascular cells, differing in biochemical structure and functions. Neutrophilic NADPH oxidase produces superoxide almost instantaneously, whereas the vascular enzyme produces superoxide in minutes to hours. Moreover, in white blood cells, superoxide has been found to transfer electrons across the membrane to extracellular oxygen, while in vascular cells, the radical anion appears to be released mainly intracellularly.
=== Covalent peptide tags === Isopeptag, a peptide which binds covalently to pilin-C protein (TDKDMTITFTNKKDAE) SpyTag, a peptide which binds covalently to SpyCatcher protein (AHIVMVDAYKPTK) SnoopTag, a peptide which binds covalently to SnoopCatcher protein (KLGDIEFIKVNK). A second generation, SnoopTagJr, was also developed to bind to either SnoopCatcher or DogTag (mediated by SnoopLigase) (KLGSIEFIKVNK) DogTag, a peptide which covalently binds to DogCatcher (DIPATYEFTDGKHYITNEPIPPK) and can react as an internal tag in loops of proteins. DogTag can also covalently bind to SnoopTagJr, mediated by SnoopLigase. SdyTag, a peptide which binds covalently to SdyCatcher protein (DPIVMIDNDKPIT). SdyTag/SdyCatcher has a kinetic-dependent cross-reactivity with SpyTag/SpyCatcher.
Sources: en.wikipedia.org
https://www.nobelprize.org/prizes/medicine/2023/press-release/ 2025: South African-born physicist and space scientist Michele Dougherty is appointed Astronomer Royal for the United Kingdom, becoming the first woman appointed to the role in its 350-year history. 2025: American biologist Mary E. Brunkow receives the Nobel Prize in Physiology or Medicine for her studies of the FOXP3 gene, which was significant to future studies of peripheral immune tolerance. She shared this award with immunologists Fred Ramsdell and Shimon Sakaguchi. 2026: Kazakhstan launches its first all female Space Isolation Experiment, SANA-1, at the National Space Center.
The Scottish Government reaffirms its wish to see the Gender Recognition Reform (Scotland) Bill enacted. 11 May – Scotland's warmest day of the year so far is recorded by the Met Office, with a temperature of 25.7 °C at Cassley. 13 May – At the High Court in Kilmarnock, Uber driver Kunathilinghan Mohanthas is sentenced to seven years in prison for killing Christopher Hanton, who he left for dead in Glasgow city centre after ordering him out of his car and knocking him over as he performed a three-point turn in August 2023. 14 May – MSPs unanimously approve the Housing Cladding Remediation Bill with 116 votes in favour of the legislation that seeks to address problems with cladding on buildings and avoid a similar incident to the Grenfell Tower fire in Scotland. 15 May – The Scottish Government declares a national housing emergency during a parliamentary debate at Holyrood, citing UK government budget cuts and austerity as the reasons for a shortage in housing. Justice Secretary Angela Constance confirms that the Scottish Government are to seek powers to facilitate the early release of prisoners in order to prevent overcrowding in prisons. The rules would only apply to those serving under four years and would not apply to those convicted of sexual or domestic violence related offences. 18 May – Four police officers are injured and 19 arrests made in Glasgow city centre as fans celebrate after Celtic win the Premiership.
=== Pharmacokinetics === Metabolism of ciprofol occurs primarily in the liver through oxidation, glucuronidation, and sulfation, resulting in the formation of the inactive metabolite M4-glucuronide, which is excreted renally. It is not necessary to adjust the dose in people with mild or moderate renal impairment, or in those with mild or moderate hepatic impairment. In elderly people, a slightly lower dose (0.3 mg/kg) appears to be similar in efficacy to the higher doses administered to younger people but is associated with fewer adverse effects. Ciprofol has a short elimination half-life, generally between 2 and 4 hours. Owing to its rapid metabolism and high clearance, the drug does not tend to accumulate in the body, even during prolonged infusions.
=== Diagnostic screening === In the case of life-threatening symptoms, unconsciousness, or bizarre behavior in an emergency situation, screening for common drugs and toxins may help find the cause, called a toxicology test or tox screen to denote the broader area of possible substances beyond just self-administered drugs. These tests can also be done post-mortem during an autopsy in cases where a death was not expected. The test is usually done within 96 hours (4 days) after the desire for the test is realized. Both a urine sample and a blood sample may be tested. A blood sample is routinely used to detect ethanol/methanol and ASA/paracetamol intoxication. Various panels are used for screening urine samples for common substances, e.g. triage 8 that detects amphetamines, benzodiazepines, cocaine, methadone, opiates, cannabis, barbiturates and tricyclic antidepressants. Results are given in 10–15 min. Similar screenings may be used to evaluate the possible use of date rape drugs. This is usually done on a urine sample.
For example, Nature published a total of 1,782 articles in the 2015/2016 biennium (902 articles in 2015 and 880 in 2016); and 74,090 references listed by articles published (by any journal) in 2017 were sourced from within the group of 1,782 articles that Nature had published during the previous two years. These figures yielded an impact factor of
Sources: en.wikipedia.org
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.
It is not approved as a prescription drug in the United States or the European Union for any indication. Regulatory status can differ by country, and it is often sold as a research chemical or in unapproved products. Such products are not equivalent to an approved medicine.
In the studies reported so far, AOD9604 does not appear to act through the growth hormone receptor and has not shown the typical IGF-1 increase caused by full-length hGH. Human data are limited, so this remains an area of uncertainty. It should not be assumed to have the same effects as hGH.
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.